Opinion: State Prescription Drug Affordability Boards could end up limiting access to the life-saving cystic fibrosis medication Trikafta

I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic fibrosis drug Trikafta. Five years later, the worst parts of my CF are gone. I recently recovered from a viral infection that provoked a pneumonia-like illness without landing in a hospital tied to an oxygen tank. A decade ago, I would have had a vastly different outcome. Along with hundreds of other people with CF, I have also become a parent since Trikafta hit the market. The CF community’s baby-boom we’ve all worked toward has happened thanks to this drug.

But access to Trikafta is now at risk for several hundred people with CF, because of what some might consider to be good intentions.

Read the rest…